Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pterin‑6‑yl‑methyl‑monophosphate is a synthetic small molecule belonging to the class of pterins and derivatives. It features a pterin ring system linked via a methylene group to a monophosphate moiety. This compound is primarily used as an experimental or discovery agent in biochemical research and drug discovery. Its main known biological activity is as an inhibitor of bacterial dihydropteroate synthetase (DHPS), an enzyme essential for folate biosynthesis in bacteria but absent in mammals. By inhibiting DHPS, it can disrupt folate production, which is critical for cell growth and survival in prokaryotes[1][5][7]. There are no approved clinical indications or marketed formulations for this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pterin-6-yl-methyl-monophosphate.